In conclusion: When NP says “the data is still being evaluated to find more positive aspects ” he is saying: “we have found that the primary end point for mild-moderate at day 14 won’t really convey the effectiveness of Leronlimab and we will need to discriminate between severity of conditions and recovery timeline in order to better demonstrate it to FDA”

Read More: https://investorshangout.com/post/view?id=584...z6TprHImBc

I disagree with this interpretation. It goes against the letter and spirit of what was said. You take out of the context two separate phrases and create meaning which is simply not there. There is absolutely no reason to speculate that day 14 won't show any significant difference with placebo. It's just not in the transcript. Moreover, elementary common sense tells me that if leron patients did much better than the place group on day three they will be better on days 7 and 14 as well.